$TRAW News

Last published 2mo ago

2mo agoTRAWTraws Pharma Reports Q2 2026 Financial Results and Provides Business HighlightsGlobeNewswireAdvancing tivoxavir marboxil toward MHRA resubmission in Q3 2026 with a revised toxicology package, supporting initiation of the Phase 2a human influenza Challenge studyCompleted the April 2026 private placement and
4mo agoTRAWTraws Pharma Provides Updated Guidance on Influenza Prophylaxis ProgramGlobeNewswireNEWTOWN, Pa., June 22, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, Traws, the Company)), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today
5mo agoTRAWTraws Pharma Provides Regulatory Update on Influenza ProgramGlobeNewswireNEWTOWN, Pa., June 12, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW, the Company)), a clinical-stage biopharmaceutical company developing novel therapies for critical global viral threats, today announced
5mo agoTRAWTraws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease OutbreaksGlobeNewswireBroad-spectrum antiviral agent with potential utility against Hantavirus, Ebola and Lassa Utilizing a novel dual-strike mechanism, the proprietary combination agent has the potential to deliver a low pill burden option
6mo agoTRAWTraws Pharma Provides Business Highlights and Reports Q1 2026 Financial ResultsGlobeNewswirePrivate financing of up to $60M offering of common stock (with $10M upfront) and milestone-based warrants expected to support operations into Q1 2027 Tivoxavir marboxil advancing towards a human influenza challenge
6mo agoTRAWTraws Pharma to Advance Potential Clinical Candidates for the Treatment of Hantavirus InfectionsGlobeNewswireNEWTOWN, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical
7mo agoTRAWTraws Pharma Reports Full Year 2025 Results and Provides Business HighlightsGlobeNewswireTivoxavir marboxil advancing towards a human influenza challenge trial as a once-monthly prophylactic agent, building on broad preclinical antiviral activity, Ratutrelvir topline Phase 2a data show a differentiated
7mo agoTRAWTraws Pharma Announces Up to $60 Million Private Placement FinancingGlobeNewswireFinancing led by Sirenia Capital Management LP advances Traws Pharma's influenza program through a human challenge trial for tivoxavir marboxil in the United Kingdom NEWTOWN, Pa., April 15, 2026 (GLOBE NEWSWIRE)
8mo agoTRAWTraws Pharma Completes Analysis of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients and Provides Updates for Additional Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal InfluenzaGlobeNewswireCompleted clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events and no viral rebounds with equivalent time to sustained symptom resolution; results were
9mo agoTRAWTraws Pharma Completes Enrollment of Ratutrelvir Clinical Study in PAXLOVID®-Eligible and Ineligible COVID-19 Patients; Announces Plans for Added Indication for Tivoxavir Marboxil as a Prophylactic Treatment for Seasonal InfluenzaGlobeNewswireOngoing clinical results with ratutrelvir confirm a differentiated profile versus PAXLOVID® with fewer adverse events, no viral rebounds to date and faster time to sustained symptom resolution; results recapitulated
10mo agoTRAWTraws Pharma Files Tivoxavir Marboxil Investigational New Drug (IND) Application for Influenza Therapy, and Provides Updated Results from the Ongoing Clinical Study of Ratutrelvir in PAXLOVID®-Eligible and Ineligible COVID-19 PatientsGlobeNewswireIND filing of tivoxavir marboxil represents final step for formal consideration by the Center for the Biomedical Advanced Research and Development Authority (BARDA) for inclusion in strategic stockpile Updated clinical
11mo agoTRAWTraws Pharma Reports Positive Interim Clinical Data with Ratutrelvir Versus PAXLOVID™, Shows Activity in PAXLOVID-Ineligible COVID-19 PatientsGlobeNewswireRatutrelvir shows a differentiated profile versus PAXLOVID™ with fewer adverse events and no viral rebounds Activity shown in Paxlovid®-ineligible patients, representing a significant population with few
12mo agoTRAWTraws Pharma Reports Third Quarter 2025 Results and Business HighlightsGlobeNewswireProgressing Phase 2 studies for ratutrelvir, a ritonavir-free, protease inhibitor regimen in development for Acute and Long COVID with expected top line data by year end Significant intellectual property and other
1y agoTRAWChemDiv Extends CMC Services Collaboration for Ratutrelvir, a Potential Best-in-Class COVID-19 Therapeutic Advancing in Phase 2 Clinical TrialsPR NewswireChemDiv, a global provider of integrated drug discovery solutions, today announced the extension of its Chemistry, Manufacturing and Controls (CMC)...
1y agoTRAWDover, Delaware -- Expert Systems Inc., a leading life sciences accelerator, Supports Traws Pharma Phase 2 Clinical Studies of Ratutrelvir -- a Novel Ritonavir-Free Antiviral for COVID-19.PR NewswireExpert Systems Inc., a leading life sciences accelerator, announced its continued support for Traws Pharma (NASDAQ: TRAW) as the company initiates...
1y agoTRAWTraws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025GlobeNewswireNon-inferiority trial versus PAXLOVID® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment Separate
1y agoTRAWTraws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key ExecutivesGlobeNewswireNEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical
1y agoANVS TRAWAnnovis Appoints Mark Guerin as Chief Financial OfficerGlobeNewswireMALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc.
1y agoTRAWTraws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025GlobeNewswireNon-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID® Separate
1y agoTRAWTraws Pharma, Inc. (TRAW) Q2 2025 Earnings Call TranscriptEarnings Call Transcripts
1y agoTRAWTraws Pharma Reports Second Quarter 2025 Results and Business HighlightsGlobeNewswireAdvancing novel programs for respiratory viruses that pose pandemic threats or risk of serious illness, including SARS CoV2 (ratutrelvir) and influenza (Tivoxavir marboxil, TXM) Prioritization of ratutrelvir, a
1y agoTRAWTraws Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 14, 2025GlobeNewswireNEWTOWN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical
1y agoTRAWTraws Pharma Advances Antiviral Pipeline with Multiple Regulatory SubmissionsGlobeNewswirePhase 2 protocol submitted to HREC to evaluate tivoxavir marboxil (TXM) in a combined seasonal and bird flu study in the Southern Hemisphere Briefing documents submitted to FDA for a Type D meeting request to continue
1y agoTRAWTraws Pharma Announces Publication of Compelling Efficacy data in RDEB SCC Patients Treated with Legacy Oncology Drug RigosertibGlobeNewswireNEWTOWN, Pa., June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical
1y agoTRAWTraws Pharma Announces Receipt of FDA Guidance on Tivoxavir Marboxil and Reports Plans for Pursuing Stockpiling for Pandemic PreparednessGlobeNewswireNEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing novel therapies to target critical
1y agoTRAWTraws Pharma Reports First Quarter 2025 Results and Business HighlightsGlobeNewswireFDA briefing document submitted April 24, 2025 in support of a meeting to align on pathway for tivoxavir marboxil (TXM, bird flu/seasonal flu) including potential for accelerated approval utilizing the "Animal Rule"
1y agoTRAWTraws Pharma Reports Full Year 2024 Results and Business HighlightsGlobeNewswireTivoxavir marboxil's potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing FDA interaction to
1y agoIKNA IOVA TRAWTraws Pharma Announces Management UpdatesGlobeNewswireWerner Cautreels, PhD, to retire as CEO, while continuing as a Board MemberIain D. Dukes, D Phil, Executive Board Chairman, to become Interim CEO NEWTOWN, Pa., March 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc.
1y agoTRAWTraws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ETGlobeNewswireEvent to highlight the differentiated features of Traws oral small molecule product candidates: Tivoxavir Marboxil, a single dose, CAP-dependent endonuclease inhibitor for Bird FluRatutrelvir, a main protease inhibitor,
1y agoTRAWTraws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICARGlobeNewswirePreclinical and Phase 1 data suggest that ratutrelvir can be used without ritonavir and may reduce the likelihood of COVID rebound and the risk of long COVID due to a longer treatment regimenPreparations are underway for
1y agoTRAWTraws Pharma Antiviral Bird Flu Program, Tivoxavir Marboxil, Shows Positive Data in Non-human PrimatesGlobeNewswireTivoxavir marboxil (TXM), administered as a single dose in non-human primates, significantly reduced lung viremia and prevented weight loss, two key measures of antiviral activity in preclinical bird flu modelsResults
1y agoTRAWTraws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICARGlobeNewswirePoster underscores Tivoxavir Marboxil's potential for the treatment of bird flu, supported by 100% survival in a rodent challenge model, potent suppression of resistant viruses and Phase 1 dataFull dataset to be
1y agoTRAWTraws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir MarboxilGlobeNewswireNEWTOWN, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the
1y agoTRAWTraws Pharma Regains Compliance with NASDAQ Equity Listing RuleGlobeNewswireNEWTOWN, Pa., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ:TRAW) ("Traws" or "Traws Pharma"), a clinical stage biopharmaceutical company developing oral small molecules for the treatment of respiratory
1y agoTRAWTraws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird FluPR NewswireTraws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small...
1y agoTRAWExpert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral ProgramPR NewswireExpert Systems, a hybrid AI enabled drug discovery and development accelerator, announced a significant milestone in a development of Traws Pharma,...
1y agoTRAWTraws Pharma, Inc. Announces Financing up to $72.6 Million from Leading Healthcare Institutional Investors to Advance Tivoxavir Marboxil Development for H5N1 Bird Flu to ApprovalPR NewswireTraws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small...
1y agoTRAWTraws Pharma Announces Progress in Developing Tivoxavir Marboxil for H5N1 Bird FluPR NewswireTraws Pharma, Inc. (NASDAQ: TRAW) ("Traws Pharma", "Traws" or "the Company"), a clinical-stage biopharmaceutical company developing oral small...
1y agoTRAWTraws Pharma Provides Business Update and Reports Q3 2024 Financial ResultsGlobeNewswireCOVID: Phase 1 pharmacokinetic profile supports the potential for ratutrelvir to be dosed as a once-a-day, single drug, 10-day treatment course, without ritonavir, and with a lower likelihood of clinical rebound and good
2y agoTRAWExpert Systems Celebrates Milestone in Clinical Development of Tivoxavir Marboxil, Potential One-Time Influenza TreatmentPR NewswireExpert Systems, a leader in combining human and artificial intelligence to accelerate drug discovery, celebrates a key milestone in the development...
2y agoTRAWTraws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir MarboxilGlobeNewswireInvestigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability results and plasma
2y agoTRAWTraws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro InhibitorGlobeNewswireRatutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir Phase 2a study expected to begin in H1
2y agoTRAWTraws Pharma, Inc. Appoints Luba Greenwood to Board of DirectorsGlobeNewswireExperienced Life Sciences Executive Brings Strategic Expertise to Support Traws' Further Transformation and Growth Director James J Marino Also to Step Down from Traws Board After a Decade of Service
2y agoTRAWTraws Pharma, Inc. Announces Special Shareholders Meeting ResultsGlobeNewswireThree proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws' shares expected to begin trading on a split-adjusted
2y agoTRAWTraws Pharma, Inc. (TRAW) Corporate Update Call TranscriptEarnings Call Transcripts
2y agoTRAWTraws Pharma Reports Q2 2024 Financial Results, Provides Recent Business HighlightsGlobeNewswireMerger with Trawsfynydd Therapeutics, Inc ("Trawsfynydd") and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical milestones, put
2y agoTRAWTraws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ETGlobeNewswireNEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. ("Traws" or "Traws Pharma"), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer,
2y agoTRAWTraws Pharma's ICAR Poster Highlights Potency of COVID-19 CandidateGlobeNewswireNEWTOWN, Pa., May 23, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. ("Traws" or "Traws Pharma"), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today
2y agoTRAWTraws Pharma Reports First Quarter 2024 Financial Results and Provides Business UpdateGlobeNewswireCompleted acquisition of Trawsfynydd and concurrent $14 million Capital Raise Excellent pipeline progress, led by candidates for COVID 19, influenza, and oncology programs Poised to initiate Phase 2 studies in H2 2024
2y agoTRAWTraws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID TherapyGlobeNewswireInvestigational travatrelvir demonstrated preclinical activity against multiple SARS-CoV-2 variants Orally administered novel protease inhibitor does not require ritonavir co-administration First-in-Human study to